Literature DB >> 23294898

Comparison of demographic, clinical, and laboratory parameters between patients with sustained normotension, white coat hypertension, masked hypertension, and sustained hypertension.

Baris Afsar1.   

Abstract

BACKGROUND: After measurement of office blood pressure (BP) and ambulatory BP monitoring (ABPM), 4 groups of patients were identified namely: (i) sustained normotensive patients (BPs are normal both clinically and by ABPM); (ii) white coat hypertensive patients (clinical BP were above limits, but ABPM were normal); (iii) masked hypertensive patients (clinical BP were normal, but ABPM were high); (iv) sustained hypertensive patients (both office and ABPM were high). The exact pathophysiologic mechanisms of these conditions are not exactly known. Besides in the literature there are only few studies that compare the 4 groups of patients together. Thus the study was carried out to compare patients with sustained normotension (SNT), white coat hypertension (WCHT), masked hypertension (MHT), and sustained hypertension (SHT).
METHODS: All patients underwent history taking, physical examination, laboratory analysis, and ABPM. They were referred to the cardiology department for echocardiographic evaluation.
RESULTS: In total 85 patients with SNT, 112 patients with WCHT, 31 patients with MHT, and 81 patients with SHT were included. Going from SNT to SHT, body mass index (p<0.0001), waist circumference (p<0.0001), fasting blood glucose (p=0.002), and uric acid (p=0.029) rose progressively. Presence of metabolic syndrome was also highest in SHT and lowest in SNT (p<0.0001).
CONCLUSION: Most of the metabolic risk factors were higher in patients with MHT and SHT when compared to SNT and WCHT. Studies are needed to determine whether metabolic risk factors play a causative role for the development of MHT and SHT.
Copyright © 2012 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23294898     DOI: 10.1016/j.jjcc.2012.11.003

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  7 in total

Review 1.  Closer look at white-coat hypertension.

Authors:  Nurver Turfaner Sipahioglu; Fikret Sipahioglu
Journal:  World J Methodol       Date:  2014-09-26

Review 2.  White Coat Hypertension: to Treat or Not to Treat?

Authors:  Cesare Cuspidi; Carla Sala; Guido Grassi; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

3.  The impact of different anthropometric measures on sustained normotension, white coat hypertension, masked hypertension, and sustained hypertension in patients with type 2 diabetes.

Authors:  Baris Afsar
Journal:  Endocrinol Metab (Seoul)       Date:  2013-09-13

4.  Diagnostic performance of clinic and home blood pressure measurements compared with ambulatory blood pressure: a systematic review and meta-analysis.

Authors:  Auttakiat Karnjanapiboonwong; Thunyarat Anothaisintawee; Usa Chaikledkaew; Charungthai Dejthevaporn; John Attia; Ammarin Thakkinstian
Journal:  BMC Cardiovasc Disord       Date:  2020-11-23       Impact factor: 2.298

Review 5.  Characteristics and control of the 24-hour ambulatory blood pressure in patients with metabolic syndrome.

Authors:  Jian-Feng Huang; Yan Li; Jinho Shin; Yook-Chin Chia; Apichard Sukonthasarn; Yuda Turana; Chen-Huan Chen; Hao-Min Cheng; Arieska Ann Soenarta; Jam Chin Tay; Tzung-Dau Wang; Kazuomi Kario; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-02-25       Impact factor: 3.738

6.  Prevalence and Related Factors of White Coat Hypertension and Masked Hypertension in Shunde District, Southern China.

Authors:  Hailan Zhu; Haoxiao Zheng; Xiaoyan Liang; Chunyi Huang; Lichang Sun; Xiong Liu; Min Qiu; Weiyi Mai; Yuli Huang
Journal:  Front Physiol       Date:  2022-07-01       Impact factor: 4.755

Review 7.  White-Coat Hypertension: the Neglected Subgroup in Hypertension.

Authors:  Cesare Cuspidi; Marijana Tadic; Giuseppe Mancia; Guido Grassi
Journal:  Korean Circ J       Date:  2018-07       Impact factor: 3.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.